Kyverna Therapeutics, Inc. (KYTX)
(Delayed Data from NSDQ)
$3.24 USD
-0.07 (-2.11%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $3.24 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
KYTX 3.24 -0.07(-2.11%)
Will KYTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KYTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KYTX
What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock
KYTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KYTX
Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise | ...
12 Health Care Stocks Moving In Tuesday's Intraday Session
Kyverna Therapeutics appoints Marc Grasso as CFO
Kyverna Therapeutics Announces Appointment of New Chief Financial Officer | KYTX Stock News
Kyverna Therapeutics names Marc Grasso, M.D., as CFO